

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: MTI META TECH INC.

Application No./Patent No.: 10/551,789

Filed/Issue Date: July 5, 2006

Entitled: FORMULATIONS FOR MEDIATING INFLAMMATION AND FOR REDUCING BLOOD CHOLESTEROL

MTI META TECH INC.

a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature



Date

Dec 12, 2007

Printed or Typed Name

Tom Clandinin

Telephone Number

(780) 437-2901

Title

CEO

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

We:

**1) Michael Thomas CLANDININ
R.R. #4
Calmar, Alberta T0C 0V0
CANADA**

**2) Eek J. PARK
3899 Nobel Drive
#1307
San Diego, California
92122-5764
UNITED STATES OF AMERICA**

or good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, do hereby sell and assign to:

**MTI META TECH INC.
11249 University Avenue
Edmonton, Alberta T6G 1Y7
CANADA**

all our right, title and interest in the United States of America, Canada, and all countries foreign thereto, in and to the invention disclosed in U.S. Patent Application No. 10/551,789, filed July 5, 2006, relating to, and entitled:

**FORMULATIONS FOR MEDIATING INFLAMMATION AND FOR REDUCING
BLOOD CHOLESTEROL**

all our right, title and interest in the United States of America, Canada, and all countries foreign thereto, in and to the invention disclosed in PCT Patent Application No. PCT/CA 2004/000375, filed on March 12, 2004, which claims priority to United States patent application No. 10/404,095, filed April 2, 2003 and to any application for patent claiming priority therefrom, and to all our corresponding right, title and interest in and to any patent issued therefrom, and to any patent issued from a continuation, continuation-in-part, re-issue, divisional or re-examination application derived, or claiming priority, from the above application.

We authorize the firm of Borden Ladner Gervais LLP to insert any further identification necessary to make this assignment suitable for recordation in the Patent Offices of any country as may be required.

SIGNED at

Edmonton

City or Town

Canada

Country

this

12

day of

Feb

2007

Michael Thomas CLANDININ

STATEMENT BY WITNESS

I, Agnes Kulinski
(name of witness)

whose full post office address
is

10722 63 St Edmonton AB
T6A 0N1

was personally present and did see **Michael Thomas CLANDININ** execute the within assignment and such assignor is personally known to me to be the person described in such document.

Kulinski

Signature of Witness

SIGNED at

^{PEJ}
~~Edmonton~~ San Diego

City or Town

^{PEJ}
USA

Country

this

09

day of

December

2007

Eek J. PARK

STATEMENT BY WITNESS

I, Sunhwa Kim
(name of witness)

whose full post office address
is

3586 Camino El Rincon #116 San Diego. CA 92130. USA.

was personally present and did see **Eek J. PARK** execute the within assignment and such assignor is personally known to me to be the person described in such document.

Kim

Signature of Witness

Please Complete and Return the Executed Form to Borden Ladner Gervais LLP